HOME >> MEDICINE >> NEWS
New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer

A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows. The drug, a molecular targeted compound called pertuzumab, works by binding to and inhibiting the function of HER2 receptors, interrupting a key pathway that leads to cancer growth.

The study, published in the February 20 issue of the Journal of Clinical Oncology, involved 41 patients with treatment-resistant prostate cancer who had experienced progression of their disease after prior chemotherapy. Patients received the drug every three weeks until disease progression. MRI and CAT scans were used to evaluate the tumors during the period of drug therapy. While no shrinkage of tumors was reported, retrospective analysis showed that survival rate was prolonged to 16.4 months with the drug as compared to a median average of 10.7 months in a historical control group with similar baseline prognostic features.

Advanced prostate cancer is difficult to treat and the drug therapies currently available to these patients have not been very effective, especially in patients whose disease has progressed after chemotherapy treatment, said David B. Agus, M.D., principal investigator of the study and research director of Cedars-Sinais Louis Warschaw Prostate Cancer Center at the Samuel Oschin Comprehensive Cancer Institute. Pertuzumab may offer a new treatment approach for these patients when it is evaluated as a tool to slow not stop or shrink -- tumor growth.

The theory is that by significantly slowing progression of the cancer, patients will experience a good quality of life for a longer period of time, said Agus. Ultimately, we hope drugs like pertuzumab will help us reach the point where cancer can be viewed as a lifetime disease to be managed much like AIDS is looked at now. This would be major shift from the current
'"/>

Contact: Simi Singer
simi.singer@cshs.org
310-423-4768
Cedars-Sinai Medical Center
16-Feb-2007


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. Early-morning Friday classes may prevent students from getting sloppy on thirsty Thursdays
3. Panel offers guidelines on skin reactions to new class of cancer drugs
4. UK researchers find new class of nontoxic cancer treatments
5. New class of HIV drug attacks previously untargeted enzyme
6. Sleep disturbances affect classroom performance
7. Simple classification can help define and predict limb-threatening diabetic infections
8. World-class Biomedical Research Center to be in West London
9. A new way of classifying addictive drugs
10. Phys ed class more effective when theres more talking
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
Cached News: